The Association of Lipoprotein(a) Levels with Atherosclerotic Cardiovascular Disease in Thailand: A Cross-Sectional Study
5
Issued Date
2025-01-01
Resource Type
ISSN
11766344
eISSN
11782048
Scopus ID
2-s2.0-105017047268
Journal Title
Vascular Health and Risk Management
Volume
21
Start Page
813
End Page
822
Rights Holder(s)
SCOPUS
Bibliographic Citation
Vascular Health and Risk Management Vol.21 (2025) , 813-822
Suggested Citation
Preechasuk L., Kongmalai T., Lapinee V., Pratumvinit B., Thongtang N. The Association of Lipoprotein(a) Levels with Atherosclerotic Cardiovascular Disease in Thailand: A Cross-Sectional Study. Vascular Health and Risk Management Vol.21 (2025) , 813-822. 822. doi:10.2147/VHRM.S544693 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/112397
Title
The Association of Lipoprotein(a) Levels with Atherosclerotic Cardiovascular Disease in Thailand: A Cross-Sectional Study
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Purpose: The optimal plasma lipoprotein(a) [Lp(a)] cutoff level for predicting atherosclerotic cardiovascular disease (ASCVD) in Southeast Asian populations remains limited. Therefore, our study aimed to identify the optimal plasma Lp(a) cutoff for predicting ASCVD in Thai patients. Patients and Methods: We conducted a retrospective analysis of patients who underwent Lp(a) measurement at Siriraj Hospital between January 2019 and August 2024. Inclusion criteria included Thai ethnicity and age ≥15 years. Baseline characteristics, comorbidities, laboratory data, and Lp(a) levels were extracted from medical records. Lp(a) levels were compared between ASCVD and non-ASCVD groups. Odds ratios (OR) for ASCVD and coronary artery disease (CAD) were calculated using Lp(a)<25 nmol/L as the reference. Results: A total of 2341 patients (age 54.4±17.7 years, 42.0% male) were included. Among them, 413 (17.6%) had ASCVD, 254 (10.9%) had CAD, 186 (7.9%) had ischemic stroke, 21 (0.9%) had peripheral arterial disease (PAD), and 14 (0.6%) had abdominal aortic aneurysm. Median Lp(a) levels (nmol/L) were significantly higher in patients with ASCVD [37.2 vs 24.4, p<0.001], CAD [43.8 vs 24.5, p<0.001], and AS [51.6 vs 25.3, p=0.002] compared to those without diseases. After adjusting for other risk factors, Lp(a)≥40 nmol/L was associated with increased risks of ASCVD [OR 1.538 (1.203–1.958)] and CAD [OR 1.877 (1.407–2.505)]. A multivariate model incorporating Lp(a)≥40 nmol/L with other risk factors demonstrated 70–80% sensitivity and specificity for predicting ASCVD and CAD. Conclusion: Elevated plasma Lp(a) levels are significantly associated with ASCVD and CAD. An Lp(a) cutoff of≥40 nmol/L predicted ASCVD and CAD risk in Thai.
